Unanswered questions in the management of axial spondyloarthritis: an opinion piece

TY - JOUR

T1 - Unanswered questions in the management of axial spondyloarthritis

T2 - an opinion piece

AU - Baraliakos, Xenofon

AU - Deodhar, Atul

N1 - Funding Information: Conflict of interest Dr. Baraliakos has received grant and research support and consultancy fees from Abbott Laboratories, Amgen, Centocor, Chugai, Merck, Novartis, Pfizer, Schering-Plough, UCB, and Wyeth. Dr. Deodhar has received grant and research support from AbbVie, Amgen, Johnson & Johnson, Novartis, and UCB, and received consultancy fees and/or speaking honoraria from AbbVie, Merck Sharp & Dohme, Novartis, Pfizer, and UCB. Funding Information: Acknowledgments The authors would like to thank Barry Weichman for assistance in drafting the manuscript and Andrew Horgan of BioScience Communications, Inc, New York, NY, for editorial assistance, activities that were supported by Novartis Pharmaceuticals. This work was supported by an unrestricted writing grant from Novartis Pharmaceuticals. No compensation was paid to the authors.

PY - 2014/10/1

Y1 - 2014/10/1

UR - http://www.scopus.com/inward/record.url?scp=84957427006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957427006&partnerID=8YFLogxK

U2 - 10.1007/s10067-014-2740-x

DO - 10.1007/s10067-014-2740-x

M3 - Editorial

C2 - 24941929

AN - SCOPUS:84957427006

VL - 33

SP - 1359

EP - 1365

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

IS - 10

ER -